CRISPR/Cas9 pioneer Chad Cowan enlists in Mustang Bio’s CAR-T quest
The tech race spawned by a blockbuster scramble to the top of the emerging CAR-T sector has inspired a tie-up between one of the pioneering scientists involved with CRISPR/Cas9 gene editing and an up-and-comer cancer drug developer that is working on a game plan to overtake the leaders — which are way out front right now.
The scientist is Chad Cowan, a researcher at the Harvard Stem Cell Institute who allied early on with the CRISPR/Cas9 team that launched CRISPR Therapeutics under gene editing star Emmanuelle Charpentier.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.